Sleep Disturbances in Long COVID: A Cohort Prospective Study
Purpose We aimed to determine the incidence of tardive sleep disturbances among patients hospitalized for COVID-19 infection, and to analyze their predictive factors. Methods It was a prospective cohort study, conducted in the department of respiratory diseases and Allergy, at Hedi Chaker University...
Gespeichert in:
Veröffentlicht in: | Sleep and vigilance 2024-12, Vol.8 (2), p.291-305 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
We aimed to determine the incidence of tardive sleep disturbances among patients hospitalized for COVID-19 infection, and to analyze their predictive factors.
Methods
It was a prospective cohort study, conducted in the department of respiratory diseases and Allergy, at Hedi Chaker University Hospital (Sfax-Tunisia). It included inpatients with laboratory-confirmed SARS-CoV-2 infection, who were discharged alive from hospital. The study protocol included 2 steps. First, patients were evaluated during their hospitalization. Then, each eligible patient was assessed 6–9 months after discharge. We thus asked them about fatigability, cognitive impairment and the following scales: the Pittsburgh Sleep Quality Index (PSQI) to assess sleep disturbances; the visual analog scale (VAS) to assess pain; the modified British Medical Research Council (mMRC scale) to evaluate dyspnea; the Patient Health Questionnaire-9 (PHQ-9) to assess depressive symptoms and the Euroqol 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) to assess the quality of life.
Results
The median age of the participants was 59 years [IQR (53–68)]. Among them, 51.2% were females. According to PSQI, the incidence of sleep disturbances after COVID was 48.8%. In multivariate analysis, predictive factors of sleep disturbances were: VAS score (
β
= 0.35;
p
= 0.007); fatigability (
β
= 1.78;
p
= 0.016); anxiety/depression (
β
= 4.25;
p
|
---|---|
ISSN: | 2510-2265 2510-2265 |
DOI: | 10.1007/s41782-024-00288-1 |